434 related articles for article (PubMed ID: 19576353)
1. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
[TBL] [Abstract][Full Text] [Related]
2. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
3. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
4. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
5. Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome.
Murdock DK; Jansen D; Juza RM; Kersten M; Olson K; Hendricks B
WMJ; 2006 Jul; 105(5):22-5. PubMed ID: 16933409
[TBL] [Abstract][Full Text] [Related]
6. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
7. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
8. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
9. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
10. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
11. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
12. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors.
Gegick CG; Altheimer MD
Curr Med Res Opin; 2004 Jun; 20(6):919-30. PubMed ID: 15200751
[TBL] [Abstract][Full Text] [Related]
15. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
16. Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Mehta A; Shah U; Parikh K; Chag M; Baxi H; Chandarana A; Naik A; Naik A; Shah K; Goyal R
Can J Physiol Pharmacol; 2007 Jun; 85(6):628-33. PubMed ID: 17823625
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones and blood lipids in type 2 diabetes.
van Wijk JP; de Koning EJ; Martens EP; Rabelink TJ
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1744-9. PubMed ID: 12907465
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.
Wang CH; Ting MK; Verma S; Kuo LT; Yang NI; Hsieh IC; Wang SY; Hung A; Cherng WJ
Am Heart J; 2006 Dec; 152(6):1051.e1-8. PubMed ID: 17161050
[TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.
Parhofer KG; Otto C; Geiss HC; Laubach E; Göke B
Exp Clin Endocrinol Diabetes; 2005 Jan; 113(1):49-52. PubMed ID: 15662596
[TBL] [Abstract][Full Text] [Related]
20. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
